Baxter to Take Over Synovis - Analyst Blog
December 16 2011 - 8:15AM
Zacks
Baxter International (BAX) recently forged a
definitive agreement to take over Synovis Life
Technologies (SYNO), a well-known provider of mechanical
and biological products for the repair of soft tissue utilized in a
large number of surgical operations. With this acquisition, Baxter
further expands its offerings in the area of biosurgery and
regenerative treatment.
The Synovis product line includes Tissue-Guard and Varitas
Collagen Matrix. The company’s offerings are used in several
procedures, such as hernia repair, vascular surgery and surgery for
obesity. Other products, such as Coupler, Flow Coupler and Gem
Microclip, are utilized for procedures like sealing minute blood
vessels. Synovis’ latest area of expertise is wound management and
orthopedic products.
Synovis had annual revenues of about $70 million in 2010. Baxter
anticipates sales growth for Synovis’ offerings to be accretive to
its future top-line. Baxter also expects the deal to be dilutive to
its fiscal 2012 earnings by about 4 cents. The acquisition is
forecast to be neutral for its 2013 earnings and turn subsequently
accretive.
The Board of Synovis has unanimously agreed to proceed with the
deal. It recommends that its shareholders approve the transaction
at an offer price of $28 per share; thereby valuing the company at
$325 million, or about $260 million, after accounting for net
cash.
Baxter anticipates that the deal will be closed in the first
quarter of fiscal 2012. The transaction is contingent to
shareholder approval, closing clauses and expiration of waiting
period as per Hart-Scott-Rodino Antitrust Improvement Act.
The news regarding Baxter still remains mixed. On the positive
side, Baxter’s focus on life-sustaining products, which are not
commoditized, partly insulates it from an economic downturn. The
company is able to generate recurring revenues, and consistent cash
flow, due to its focus on chronic diseases.
On the flip side, despite recent stability in Plasma Proteins
and Antibody Therapy sub-segments, we are concerned about
sluggishness in sales, a slightly somber outlook for some hospital
spending and tightening of reimbursement.
Improved execution has lifted sentiment somewhat toward Baxter.
The company is a good bet for value investors willing to wait as
fundamentals improve further. Among others, it competes with
Becton, Dickinson and Co. (BDX) in certain niches.
We are currently Neutral on the stock, backed by a short-term Zacks
#3 Rank (Hold).
BAXTER INTL (BAX): Free Stock Analysis Report
BECTON DICKINSO (BDX): Free Stock Analysis Report
SYNOVIS LIF TEC (SYNO): Free Stock Analysis Report
Zacks Investment Research
Synovis Life Technologies, Inc. (MM) (NASDAQ:SYNO)
Historical Stock Chart
From May 2024 to Jun 2024
Synovis Life Technologies, Inc. (MM) (NASDAQ:SYNO)
Historical Stock Chart
From Jun 2023 to Jun 2024